Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary – Aarti Drugs Limited** Aarti Drugs faces its most acute financial exposure through regulatory compliance risk (10.0/10 score), with estimated remediation costs of ₹4–13 crore tied to SEBI BRSR disclosure obligations and potential Extended Producer Responsibility (EPR) applicability under Indian waste management rules. The company's critical gap is missing Scope 1 and Scope 2 emissions data despite BRSR Core Expansion mandates for large manufacturers, creating immediate non-compliance risk including potential SEBI enforcement action, stock exchange censure, or delisting for top-tier listed entities. EPR exposure (6.5/10) presents undefined but material liability—pharmaceutical and chemical product packaging obligations under EPR rules remain unquantified and could trigger significant reverse logistics and end-of-life management costs once clarified. Without urgent emissions accounting, EPR classification clarity, and BRSR alignment, the company risks reputational damage, regulatory penalties, and access-to-capital constraints alongside the stated ₹4–13 crore compliance cost burden.
Source: Aarti Drugs Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.